Paper Details

  1. Home
  2. Paper Details

Drug delivery strategies for the treatment of Helicobacter pylori infections.

Author: ConwayB R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Helicobacter pylori is one of the most common pathogenic bacterial infections, colonising an estimated half of all humans. It is associated with the development of serious gastroduodenal disease - including peptic ulcers, gastric lymphoma and acute chronic gastritis. Current recommended regimes are not wholly effective and patient compliance, side-effects and bacterial resistance can be problematic. Drug delivery to the site of residence in the gastric mucosa may improve efficacy of the current and emerging treatments. Gastric retentive delivery systems potentially allow increased penetration of the mucus layer and therefore increased drug concentration at the site of action. Proposed gastric retentive systems for the enhancement of local drug delivery include floating systems, expandable or swellable systems and bioadhesive systems. Generally, problems with these formulations are lack of specificity, limited to mucus turnover or failure to persist in the stomach. Gastric mucoadhesive systems are hailed as a promising technology to address this issue, penetrating the mucus layer and prolonging activity at the mucus-epithelial interface. This review appraises gastroretentive delivery strategies specifically with regard to their application as a delivery system to target Helicobacter. As drug-resistant strains emerge, the development of a vaccine to eradicate and prevent reinfection is an attractive proposition. Proposed prophylactic and therapeutic vaccines have been delivered using a number of mucosal routes using viral and non-viral vectors. The delivery form, inclusion of adjuvants, and delivery regime will influence the immune response generated.
Paper Details　
Original Abstract of the Article :
Helicobacter pylori is one of the most common pathogenic bacterial infections, colonising an estimated half of all humans. It is associated with the development of serious gastroduodenal disease - including peptic ulcers, gastric lymphoma and acute chronic gastritis. Current recommended regimes are ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1381612053381819

データ提供：米国国立医学図書館（NLM）

Helicobacter pylori: A Stubborn Desert Dweller

Helicobacter pylori, a resilient bacterium that often colonizes the human stomach, can be a persistent foe. Imagine this bacterium as a stubborn desert dweller, thriving in the harsh environment of the stomach. This research delves into the challenges of treating Helicobacter pylori infections, exploring innovative drug delivery strategies to target this resilient bacterium.

Drug Delivery Strategies: New Weapons in the Fight

Current treatments for Helicobacter pylori infections face challenges such as patient compliance, side effects, and bacterial resistance. It's like trying to evict a stubborn desert inhabitant who has dug in for the long haul. This research explores promising drug delivery strategies, such as gastroretentive systems, which aim to improve the efficacy of existing and emerging treatments. The authors propose that these strategies could act like a guided missile, delivering the right dose of medication directly to the target site.

Targeting Helicobacter pylori: A New Frontier

The development of effective drug delivery systems for Helicobacter pylori is crucial for addressing this common and often challenging infection. Like a resourceful explorer navigating a desert, researchers are continuously seeking new ways to target and eradicate this stubborn bacterium. This research provides a valuable roadmap for future developments in drug delivery strategies, offering hope for a more effective and targeted approach to treating Helicobacter pylori infections.

Dr.Camel's Conclusion

This research underscores the ongoing quest for effective treatments against Helicobacter pylori, a resilient bacterium that often colonizes the human stomach. Researchers are exploring new drug delivery strategies, like a skilled desert navigator seeking a hidden oasis, to conquer this persistent foe. These advancements offer hope for a future where treating Helicobacter pylori infections becomes more effective and less burdensome for patients.

Date :
  1. Date Completed 2005-04-06
  2. Date Revised 2019-07-28
Further Info :

Pubmed ID

15777232

DOI: Digital Object Identifier

10.2174/1381612053381819

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.